Keyword Analysis & Research: asco gu 2024
Keyword Research: People who searched asco gu 2024 also searched
Search Results related to asco gu 2024 on Search Engine
-
2024 ASCO Genitourinary Cancers Symposium: Celebrating 20 …
https://connection.asco.org/magazine/features/2024-asco-genitourinary-cancers-symposium-celebrating-20-years
WebNov 20, 2023 · 2024 ASCO Genitourinary Cancers Symposium: Celebrating 20 Years. Nov 20, 2023. On January 25-27, genitourinary (GU) cancer specialists from around the world will gather for the 20 th year of the ASCO Genitourinary Cancers Symposium, where they will engage with the latest high-impact science, multidisciplinary expertise, and evidence …
DA: 80 PA: 80 MOZ Rank: 81
-
Program Guide – ASCO Meeting Program Guide
https://meetings.asco.org/meetings/2024-genitourinary-cancers-symposium/315/program-guide/scheduled-sessions
WebResults. The 2024 ASCO Genitourinary Cancers Symposium is funded through Conquer Cancer®, the ASCO Foundation, by these generous sponsorship donors.
DA: 76 PA: 48 MOZ Rank: 93
-
ASCO GU 2024 - urotoday.com
https://www.urotoday.com/conference-highlights/asco-gu-2024.html
WebASCO GU 2024: Neoadjuvant Nivolumab + Ipilimumab in Cisplatin-Ineligible Patients with Upper Tract Urothelial Cancer: Updated Results. ASCO GU 2024: Sequential Endoluminal Gemcitabine and Docetaxel vs BCG for the Treatment of High-grade UTUC. ASCO GU 2024: A Phase II Study of Tislelizumab Monotherapy as Neoadjuvant Treatment for …
DA: 71 PA: 65 MOZ Rank: 62
-
ASCO GU 2024: Advances in Prostate Cancer
https://www.cancertherapyadvisor.com/indepth/asco-gu-2024-advances-in-prostate-cancer/
WebFeb 12, 2024 · Research presented at the ASCO Genitourinary Cancers Symposium 2024 may inform the treatment of prostate cancer.
DA: 13 PA: 98 MOZ Rank: 39
-
Global GU Meeting Will Highlight New Approaches to Detect and …
https://society.asco.org/about-asco/press-center/news-releases/global-gu-meeting-will-highlight-new-approaches-detect-and
WebJan 10, 2024 · ALEXANDRIA, Va. – The latest research exploring innovative approaches for the detection and treatment of prostate, bladder, and kidney cancers will be highlighted in the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium’s official Press Program.
DA: 47 PA: 36 MOZ Rank: 78
-
ASCO GU 2024: Systemic Treatment of High-Risk Biochemical …
https://www.urotoday.com/conference-highlights/asco-gu-2024/asco-gu-2024-prostate-cancer/149342-asco-gu-2024-systemic-treatment-of-high-risk-biochemical-recurrence.html
Web(UroToday.com) The 2024 GU ASCO annual meeting featured a session examining the emerging evidence in localized and recurrent prostate cancer, including a presentation by Dr. Channing Paller discussing systemic treatment of high-risk biochemical recurrence.
DA: 91 PA: 34 MOZ Rank: 11
-
Advances in Treating Kidney Cancer and Metastatic Prostate …
https://www.cancer.net/blog/2024-01/2024-genitourinary-cancers-symposium
WebJan 25, 2024 · The 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium will be held January 25 to 27 in San Francisco, California. This meeting features research in the treatment and care of people with genitourinary (GU) cancers, which is a group of cancers that occur in the urinary tract or the male …
DA: 52 PA: 59 MOZ Rank: 49
-
ASCO GU 2024: CONTACT-02: Phase 3 Study of Cabozantinib
https://www.urotoday.com/conference-highlights/asco-gu-2024/asco-gu-2024-prostate-cancer/149324-asco-gu-2024-contact-2-phase-3-study-of-cabozantinib-atezolizumab-vs-second-novel-hormonal-therapy-in-patients-with-mcrpc.html
Web(UroToday.com) The 2024 GU ASCO annual meeting featured an oral prostate cancer session and a presentation by Dr. Neeraj Agarwal discussing CONTACT-02, a phase 3 study of cabozantinib + atezolizumab vs second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
DA: 75 PA: 6 MOZ Rank: 75
-
ASCO GU Symposium 2024 Coverage | GU Oncology Now
https://guoncologynow.com/conference/asco-gu-symposium-2024
WebMar 7, 2024 · Read in-depth coverage of the 2024 ASCO GU Symposium from GU oncology experts and key opinion leaders.
DA: 64 PA: 43 MOZ Rank: 17
